Researchers presented a novel experimental “five-in-one” compound at the European Association for the Study of Diabetes (EASD) 2025 Annual Meeting that combined five metabolic actions and produced stronger glucose control and weight loss than current therapies in early animal tests. Daniela Liskiewicz, PhD, of the Institute for Diabetes and Obesity at Helmholtz Zentrum München and the German Center for Diabetes Research reported that the engineered “quintuple agonist” links GLP‑1 and GIP receptor agonism with lanifibranor, a molecule that activates three PPAR receptors (PPAR‑alpha, PPAR‑delta and PPAR‑gamma), to target metabolism on multiple fronts.
The compound is designed to do more than mimic a single hormone: the GLP‑1 and GIP components act on appetite, insulin secretion and early post‑meal glucose responses, while the triple‑PPAR activity influences fat handling, energy use and long‑term insulin sensitivity. According to the researchers, combining these five mechanisms produces synergistic effects in the brain and adipose tissue that exceed the impact of giving each component separately.
That matters because current breakthrough drugs such as semaglutide (a GLP‑1 agonist) and tirzepatide (a dual GIP/GLP‑1 agonist) primarily reduce appetite, slow gastric emptying and boost insulin release-powerful effects but focused on one or two pathways. Liskiewicz noted, “PPARs are master regulators of metabolism expressed in key metabolic tissues,” underlining why adding PPAR activation could address deeper metabolic dysfunction.
Early studies in obese, insulin‑resistant mice showed the quintuple agonist produced greater reductions in blood glucose and body weight than even the most effective existing agents. Researchers caution, however, that these are preclinical proof‑of‑concept results: rigorous human trials are required to establish safety, dosing and long‑term benefits across diverse populations.
The work signals a shift toward multi‑target, precision approaches for diabetes and obesity treatment-promising, but still at an early stage. This report is informational and not a substitute for medical advice; patients should consult their doctors about treatment options.
Original Source: https://www.ndtv.com/health/beyond-glp-1-five-in-one-compound-more-effective-than-semaglutide-for-diabetes-and-weight-loss-11440894#publisher=newsstand
Category:
Tags:
Publish Date: 2026-05-03 00:26:00
